Last reviewed · How we verify

NCT06193642: 4FRAILTY

Increasing Knowledge on Osteogenesis Imperfecta by Collecting Epidemiological Data

Active, enrolled NA Last updated 25 March 2025
What this trial tests

NA trial testing experimental in Osteogenesis Imperfecta in 33 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
20 January 2023
Primary endpoint
30 November 2028
30 November 2028

Quick facts

Lead sponsorIstituto Ortopedico Rizzoli
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment33
Start date20 January 2023
Primary completion30 November 2028
Estimated completion30 November 2028
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Istituto Ortopedico Rizzoli — full company profile →

Who can join

Adults 8 to 60, any sex, with Osteogenesis Imperfecta. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

interventional pilot study with the enrollment of patients affected by Osteogenesis Imperfecta

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of experimental

Trials testing the same drug.

Other recruiting trials for Osteogenesis Imperfecta

Currently open trials in the same condition.

Other Istituto Ortopedico Rizzoli trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06193642.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing